AP1189   Click here for help

GtoPdb Ligand ID: 11292

Synonyms: AP-1189 | example 19 [WO2007141343A1]
Compound class: Synthetic organic
Comment: AP1189 is a biased agonist of melanocortin (MC) receptors. It was designed to elicit the proresolving properties of the MC1 and MC3 receptors in inflammation, whilst sparing their melanogenic effects [2]. This is achieved by bias towards ERK1/2 phosphorylation and and Ca2+ mobilisation rather than inducing canonical cAMP production. The chemical structure is claimed in Action Pharma's patent WO2007141343A1 (compound 2/example 19) [1].

SARS-CoV-2 and COVID-19: The proresolving activity of AP1189 is being investigated as a mechanism to combat the dysfunctional immune response in COVID-19 patients.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 124.31
Molecular weight 298.12
XLogP 2.81
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES NC(=N/N=C\C=C\c1cccn1c1ccccc1[N+](=O)[O-])N
Isomeric SMILES NC(=N/N=C\C=C\c1cccn1c1ccccc1[N+](=O)[O-])N
InChI InChI=1S/C14H14N6O2/c15-14(16)18-17-9-3-5-11-6-4-10-19(11)12-7-1-2-8-13(12)20(21)22/h1-10H,(H4,15,16,18)/b5-3+,17-9-
InChI Key ZSDGHWLLLGYAJV-LDRJOUGUSA-N
References
1. Boman A, Jonassen TEN, Lundstedt T. (2007)
Phenyl pyrrole aminoguanidine derivatives.
Patent number: WO2007141343A1. Assignee: Action Pharma A/S. Priority date: 09/06/2006. Publication date: 13/12/2007.
2. Montero-Melendez T, Gobbetti T, Cooray SN, Jonassen TE, Perretti M. (2015)
Biased agonism as a novel strategy to harness the proresolving properties of melanocortin receptors without eliciting melanogenic effects.
J Immunol, 194 (7): 3381-8. [PMID:25725103]